↓ Skip to main content

Dove Medical Press

The effects of black cohosh on the regulation of estrogen receptor (ERα) and progesterone receptor (PR) in breast cancer cells

Overview of attention for article published in Breast cancer targets and therapy, January 2018
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)

Mentioned by

policy
1 policy source
twitter
2 X users
video
1 YouTube creator

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
37 Mendeley
Title
The effects of black cohosh on the regulation of estrogen receptor (ERα) and progesterone receptor (PR) in breast cancer cells
Published in
Breast cancer targets and therapy, January 2018
DOI 10.2147/bctt.s144865
Pubmed ID
Authors

Monica Szmyd, Victoria Lloyd, Kelly Hallman, Katie Aleck, Viktoria Mladenovik, Christina McKee, Mia Morse, Tyler Bedgood, Sumi Dinda

Abstract

The North American plant Cimicifuga racemosa, also known as black cohosh (BC), is a herb that recently has gained attention for its hormonal effects. As the usage of hormone replacement therapy is declining due to its adverse effects in women with cancer, many are turning to herbal remedies like BC to treat menopausal symptoms. It is crucial to determine whether the effects of BC involve estrogen receptor-alpha (ERα). Previous studies from our laboratory have shown ERα to be a possible molecular target for BC. In this study, we examined the effects of BC (8% triterpene glycosides) alone and in combination with hormones and antihormones on the cellular viability, expression of ERα and progesterone receptor (PR)-A/B, and cytolocalization of ERα in ER (+) and PR-A/B (+) T-47D breast cancer cells. Cells were cultured and proteins were extracted and quantified. Western blot analysis revealed alterations in the expression of ERα and PR after treatment with BC (5-100 µM). BC induced a concentration-dependent decrease in ERα and PR protein levels when compared to the control. Image cytometric analysis with propidium iodide staining was used to enumerate changes in T-47D cell number and viability. A decrease in T-47D cell viability was observed upon treatment with 5-100 µM BC. The ideal concentration of BC (100 µM) was used in combination with hormones and antihormones in an effort to further understand the possible similarities between this compound and other known effectors of ERα and PR. After a 24-hour concomitant treatment with and/or in combination of BC, estradiol, ICI 182, 780, and Tamoxifen, downregulation of ERα and PR protein levels was observed. Delineating the role of BC in the regulation of ERα, PR, as well as its mechanisms of action, may be important in understanding the influence of BC on hormone receptors in breast cancer.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 37 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 7 19%
Student > Doctoral Student 5 14%
Student > Master 4 11%
Lecturer 3 8%
Student > Ph. D. Student 3 8%
Other 4 11%
Unknown 11 30%
Readers by discipline Count As %
Medicine and Dentistry 9 24%
Pharmacology, Toxicology and Pharmaceutical Science 6 16%
Biochemistry, Genetics and Molecular Biology 3 8%
Nursing and Health Professions 3 8%
Agricultural and Biological Sciences 1 3%
Other 2 5%
Unknown 13 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 October 2022.
All research outputs
#6,932,988
of 25,382,440 outputs
Outputs from Breast cancer targets and therapy
#87
of 324 outputs
Outputs of similar age
#128,517
of 449,550 outputs
Outputs of similar age from Breast cancer targets and therapy
#2
of 4 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 324 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 449,550 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.